Date: March 14, 2021	
Your Name: Xingxing Tang	
Manuscript Title: The Compound AST-003 Could Effectively Promote Apoptosis of Renal Cell Carcinoma Cells in V	ïtro
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>X</u> None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_X_None	
	2014 - 19 m		
8	Patents planned, issued or pending	X_None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
		1	
10	Leadership or fiduciary role	X None	
0555	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	<u>X</u> None	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: March 14, 2021
Your Name: Qiang Zhao
Manuscript Title: The Compound AST-003 Could Effectively Promote Apoptosis of Renal Cell Carcinoma Cells in Vitro
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>X</u> None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_X_None	
	2014 - 19 m		
8	Patents planned, issued or pending	X_None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
		1	
10	Leadership or fiduciary role	X None	
0555	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	<u>X</u> None	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: March 14, 2021	
Your Name: Jia Liu	
Manuscript Title: The Com	pound AST-003 Could Effectively Promote Apoptosis of Renal Cell Carcinoma Cells in Vitro
Manuscript number (if kn	own):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>X</u> None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_X_None	
	2014 - 19 m		
8	Patents planned, issued or pending	X_None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
		1	
10	Leadership or fiduciary role	X None	
0555	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	<u>X</u> None	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: March 14, 2021
Your Name: Shuo Wang
Manuscript Title: The Compound AST-003 Could Effectively Promote Apoptosis of Renal Cell Carcinoma Cells in Vitro
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>X</u> None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_X_None	
	2014 - 19 m		
8	Patents planned, issued or pending	X_None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
		1	
10	Leadership or fiduciary role	X None	
0555	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	<u>X</u> None	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: March 14, 2021
Your Name: Ning Zhang
Manuscript Title: The Compound AST-003 Could Effectively Promote Apoptosis of Renal Cell Carcinoma Cells in Vitro
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>X</u> None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_X_None	
	- 14 - 14 - 14 - 14 - 14 - 14 - 14 - 14		
8	Patents planned, issued or pending	X_None	
	penuing		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society,	X None	
1.000.000			
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
12		None	
13	Other financial or non- financial interests	<u>X</u> None	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: March 14, 2021
Your Name: Yong Yang
Manuscript Title: The Compound AST-003 Could Effectively Promote Apoptosis of Renal Cell Carcinoma Cells in Vitro
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_X_None	
	- 14 - 14 - 14 - 14 - 14 - 14 - 14 - 14		
8	Patents planned, issued or pending	X_None	
	penuing		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society,	X None	
1.000.000			
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
12		None	
13	Other financial or non- financial interests	<u>X</u> None	

None.

Please place an "X" next to the following statement to indicate your agreement: